Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Operations (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Cash from Operations for 7 consecutive years, with 101938000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 109.43% year-over-year to 101938000.0, compared with a TTM value of 322930000.0 through Dec 2025, down 127.25%, and an annual FY2025 reading of 322930000.0, down 127.25% over the prior year.
  • Cash from Operations was 101938000.0 for Q4 2025 at Summit Therapeutics, down from 93080000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 5191000.0 in Q4 2022 and bottomed at 101938000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 32798250.0, with a median of 22117000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations soared 156.55% in 2022, then crashed 474.86% in 2023.
  • Year by year, Cash from Operations stood at 9179000.0 in 2021, then skyrocketed by 156.55% to 5191000.0 in 2022, then plummeted by 474.86% to 19459000.0 in 2023, then tumbled by 150.13% to 48673000.0 in 2024, then plummeted by 109.43% to 101938000.0 in 2025.
  • Business Quant data shows Cash from Operations for SMMT at 101938000.0 in Q4 2025, 93080000.0 in Q3 2025, and 66744000.0 in Q2 2025.